Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Autor:	Tauro M; Tumor Biology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Shay G; Tumor Biology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Sansil SS; Translational Research Core and, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Laghezza A; Department of Pharmacy-Pharmaceutical Sciences, University of Bari 'A. Moro', Bari, Italy., Tortorella P; Department of Pharmacy-Pharmaceutical Sciences, University of Bari 'A. Moro', Bari, Italy., Neuger AM; Translational Research Core and, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Soliman H; Department of Women's Oncology and Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Lynch CC; Tumor Biology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. conor.lynch@moffitt.org.
Jazyk:	angličtina
Zdroj:	Molecular cancer therapeutics [Mol Cancer Ther] 2017 Mar; Vol. 16 (3), pp. 494-505. Date of Electronic Publication: 2017 Jan 09.
DOI:	10.1158/1535-7163.MCT-16-0315-T
Abstrakt:	Bone metastasis is common during breast cancer progression. Matrix metalloproteinase-2 (MMP-2) is significantly associated with aggressive breast cancer and poorer overall survival. In bone, tumor- or host-derived MMP-2 contributes to breast cancer growth and does so by processing substrates, including type I collagen and TGFβ latency proteins. These data provide strong rationale for the application of MMP-2 inhibitors to treat the disease. However, in vivo , MMP-2 is systemically expressed. Therefore, to overcome potential toxicities noted with previous broad-spectrum MMP inhibitors (MMPIs), we used highly selective bisphosphonic-based MMP-2 inhibitors (BMMPIs) that allowed for specific bone targeting. In vitro , BMMPIs affected the viability of breast cancer cell lines and osteoclast precursors, but not osteoblasts. In vivo , we demonstrated using two bone metastatic models (PyMT-R221A and 4T1) that BMMPI treatment significantly reduced tumor growth and tumor-associated bone destruction. In addition, BMMPIs are superior in promoting tumor apoptosis compared with the standard-of-care bisphosphonate, zoledronate. We demonstrated MMP-2-selective inhibition in the bone microenvironment using specific and broad-spectrum MMP probes. Furthermore, compared with zoledronate, BMMPI-treated mice had significantly lower levels of TGFβ signaling and MMP-generated type I collagen carboxy-terminal fragments. Taken together, our data show the feasibility of selective inhibition of MMPs in the bone metastatic breast cancer microenvironment. We posit that BMMPIs could be easily translated to the clinical setting for the treatment of bone metastases given the well-tolerated nature of bisphosphonates. Mol Cancer Ther; 16(3); 494-505. ©2017 AACR . (©2017 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu